



The Drug Utilization Review (DUR) Board Reviewed
the Following New Drugs/Classes on
November 5, 2019

Therapeutic Class	Drug Name	DURB Recommendations
Anticoagulants		
	<i>Bevyxxa (Oral) Capsule</i>	NP/PA
Bone Resorption Suppression and Related Agents		
	<i>Evenity (Subcutaneous) Injection</i>	NP/PA (for coverage on the PADL)
Antiparkinsons Agents		
	<i>Inbrija (Inhalation) Capsule</i> <i>Apokyn (Subcutaneous) Injection</i>	NP/PA
Multiple Sclerosis Agents		
	<i>Mavenclad (Oral) Tablet</i> <i>Mayzent (Oral) Tablet</i>	NP/PA
GI Motility, Chronic		
	<i>Motegrity (Oral) Tablet</i>	NP/PA
Cytokine and CAM Antagonists		
	<i>Skyrizi (Subcutaneous) Injection</i>	NP/PA
Antidepressants, Other		
	<i>Spravato (Nasal) Spray</i>	NP/PA (for coverage on the PADL)
Atypical Antipsychotics		
	<i>Rexulti (Oral) Tablet</i> <i>Abilify Maintena (Intramuscular) Injection</i>	NP/PA NP/PA (for coverage on the PDL and PADL)

DURB=Drug Utilization Review Board; P=preferred; NP=non-preferred; PA=prior authorization; PDL=Preferred Drug List; PADL=Providers' Administered Drug List